E1	Modifier:T1 Modifies:T104
E2	Or:T2 Arg:E1 Arg2:E3
E3	Modifier:T3 Modifies:T104
E4	Condition:T4 Name:T104
E5	Condition:T5 Name:T105
E7	Eq-Comparison:T7 Operator:T106 Value:T107
E8	Procedure:T8 Minimum-Count:E7 Temporality:E6
E9	Negation:T9 Negates:E10
E10	Condition:T10 Name:T179
E11	Condition:T11 Name:T109
E13	Eq-Comparison:T13 Value:T110 Unit:T111 Operator:T112
E16	Temporal-Connection:T16 Arg:E12 Arg2:E17
E17	Condition:T17 Name:T15
E18	Condition:T18 Name:T115
E19	Condition:T19 Name:T116
E20	Condition:T20 Name:T117
E21	Or:T21 Arg:E20 Arg2:E22
E22	Condition:T22 Name:T118
E23	Modifier:T23 Modifies:T119
E24	Condition:T24 Name:T119
E25	Condition:T25 Name:T120
E26	Observation:T26 Name:T121 Eq-Comparison:E27 Temporality:E28
E27	Eq-Comparison:T27 Operator:T122 Value:T123 Per:T114
E28	Eq-Comparison:T28 Operator:T124 Value:T125 Temporal-Unit:T126
E29	Temporal-Connection:T29 Arg:E28 Arg2:E30
E30	Eq-Comparison:T30 Temporal-Recency:T127
E31	Procedure:T31 Temporality:E30
E32	Drug:T32 Name:T128
E35	Observation:T35 Name:T33 Eq-Comparison:E36
E36	Eq-Comparison:T36 Operator:T129 Value:T130 Per:T34
E37	Temporal-Connection:T37 Arg:E32 Arg2:E38
E38	Eq-Comparison:T38 Temporal-Recency:T181
E39	Procedure:T39 Temporality:E38
E41	Observation:T41 Name:T131 Eq-Comparison:E42
E42	Eq-Comparison:T42 Operator:T182 Value:T183
E43	Observation:T43 Name:T132 Eq-Comparison:E45
E45	Eq-Comparison:T45 Value:T134 Unit:T135 Per:T136
E46	Observation:T46 Name:T137 Eq-Comparison:E49
E47	And:T47 Arg:E46 Arg2:E48
E48	Observation:T48 Name:T138 Eq-Comparison:E49
E49	Eq-Comparison:T49 Operator:T139 Value:T140 Unit:T44
E50	Observation:T50 Name:T141 Eq-Comparison:E51
E51	Eq-Comparison:T51 Operator:T142 Value:T143 Unit:T184
E52	Eq-Comparison:T52 Temporal-Period:T144
E53	Modifier:T53 Modifies:T145
E54	Condition:T54 Name:T145 Temporality:E52
E55	Condition:T55 Name:T146
E56	Or:T56 Arg:E55 Arg2:E60
E58	Modifier:T58 Modifies:T148
E59	Or:T59 Arg:E58 Arg2:E15
E60	Condition:T60 Name:T148
E62	Observation:T62 Name:T149 Polarity:T147
E63	Eq-Comparison:T63 Temporal-Period:T150
E64	Or:T64 Arg:T61 Arg2:T151
E66	Drug:T66 Name:T152 Temporality:E63 Dose:T61 Dose2:T151 Temporality2:E67
E67	Eq-Comparison:T67 Operator:T153 Value:T154 Temporal-Unit:T155
E68	Temporal-Connection:T68 Arg:E67 Arg2:E69
E69	Eq-Comparison:T69 Temporal-Recency:T156
E70	Study:T70 Study-Of:E71
E71	Procedure:T71 Temporality:E69
E72	Eq-Comparison:T72 Temporal-Period:T157
E73	Procedure:T73 Name:T158 Temporality:E72 Severity:T159 Polarity:T160
E75	Modifier:T75 Modifies:T158
E76	Condition:T76 Name:T162 Severity:T161
E77	Eq-Comparison:T77 Temporal-Period:T163
E78	Modifier:T78 Modifies:T165
E79	Condition:T79 Name:T165 Severity:T164 Temporality:E77
E80	Other:T80 Is-Other:E82
E81	Modifier:T81
E82	Condition:T82 Name:T166 Temporality:E83
E83	Eq-Comparison:T83 Operator:T167 Value:T168 Temporal-Unit:T169
E84	Temporal-Connection:T84 Arg:E83 Arg2:E85
E85	Study:T85
E86	Condition:T86 Name:T170
E87	Assertion:T87 Asserted:E88
E88	Negation:T88 Negates:E89
E89	Study:T89
E90	Eq-Comparison:T90 Temporal-Period:T171
E91	Modifier:T91 Modifies:T172
E92	Procedure:T92 Name:T172 Temporality:E90
E93	Eq-Comparison:T93 Temporal-Period:T173
E94	Procedure:T94 Temporality:E93
E95	Procedure:T95 Name:T174
E96	And:T96 Arg:E95 Arg2:E97
E97	Negation:T97 Negates:E98
E98	Condition:T98 Name:T175
E99	Or:T99 Arg:E98 Arg2:E101
E100	Eq-Comparison:T100 Temporal-Period:T176
E101	Procedure:T101 Name:T177 Temporality:E100
E102	Or:T102 Arg:E101 Arg2:E103
E103	Procedure:T103 Name:T178 Temporality:E100
E6	Eq-Comparison:T6 Temporal-Period:T108
E104	And:T180 Arg:E8 Arg2:E9
E12	Observation:T12 Name:T14 Specimen:T113 Eq-Comparison:E13
E14	Assertion:T40 Asserted:E32
E15	Modifier:T57 Modifies:T148
E33	Modifier:T65 Modifies:T158
E34	Negation:T74 Negates:E81
T1	Modifier 39 35	Refractory
T2	Or 42 38	or
T3	Modifier 51 47	relapsed
T4	Condition 55 51	AML
T5	Condition 108 100	Refractory disease
T7	Eq-Comparison 139 130	at least 1
T8	Procedure 155 146	treatment
T9	Negation 163 154	no
T10	Condition 173 164	remission
T11	Condition 205 192	Relapsed disease
T13	Eq-Comparison 237 222	5% or more
T16	Temporal-Connection 270 255	after
T17	Condition 280 265	remission
T18	Condition 313 294	AML
T19	Condition 352 333	myelodysplastic syndromes
T20	Condition 369 349	CMML
T21	Or 374 353	or
T22	Condition 403 382	myeloproliferative neoplasms
T23	Modifier 415 393	secondary
T24	Condition 419 397	AML
T25	Condition 430 405	ts-AML
T26	Observation 484 454	Circulating blast count
T27	Eq-Comparison 496 463	≤ 200/μL
T28	Eq-Comparison 512 478	within 10 days
T29	Temporal-Connection 521 487	prior to
T30	Eq-Comparison 527 493	first
T31	Procedure 546 512	treatment
T32	Drug 561 525	Hydroxyurea
T35	Observation 611 575	peripheral blast count
T36	Eq-Comparison 623 584	≤ 200/μL
T37	Temporal-Connection 629 590	until
T38	Eq-Comparison 643 604	first day
T39	Procedure 665 626	treatment
T41	Observation 715 673	ECOG
T42	Eq-Comparison 720 677	≤ 2
T43	Observation 759 713	Estimated creatinine clearance
T45	Eq-Comparison 774 725	≥ 50 mL/min
T46	Observation 785 734	AST
T47	And 789 738	and
T48	Observation 793 742	ALT
T49	Eq-Comparison 806 754	≤ 3.0 x ULN
T50	Observation 823 769	Bilirubin
T51	Eq-Comparison 836 781	≤ 3.0 x ULN
T52	Eq-Comparison 872 813	Active
T53	Modifier 876 817	CNS
T54	Condition 885 826	Leukemia
T55	Condition 915 852	HIV infection
T56	Or 918 855	or
T58	Modifier 936 873	hepatitis B
T59	Or 939 876	or
T60	Condition 961 898	infection
T62	Observation 992 928	viral load
T63	Eq-Comparison 1030 960	received
T64	Or 1046 974	and/or
T66	Drug 1071 998	CYP3A inducers
T67	Eq-Comparison 1086 1012	within 7 days
T68	Temporal-Connection 1095 1021	prior to
T69	Eq-Comparison 1110 1036	initiation
T70	Study 1119 1045	study
T71	Procedure 1129 1055	treatment
T72	Eq-Comparison 1159 1081	received prior
T73	Procedure 1169 1091	radiation
T75	Modifier 1228 1150	organ
T76	Condition 1277 1195	cardiac disease
T77	Eq-Comparison 1294 1208	Active
T78	Modifier 1309 1222	uncontrolled
T79	Condition 1327 1240	infection
T80	Other 1348 1257	other
T81	Modifier 1362 1269	myeloid
T82	Condition 1373 1280	malignancy
T83	Eq-Comparison 1389 1295	within 2 years
T84	Temporal-Connection 1392 1298	of
T85	Study 1398 1304	entry
T86	Condition 1450 1349	Psychiatric disorder
T87	Assertion 1461 1360	would
T88	Negation 1470 1369	preclude
T89	Study 1476 1375	study
T90	Eq-Comparison 1506 1403	Previous
T91	Modifier 1512 1409	solid
T92	Procedure 1529 1426	organ transplant
T93	Eq-Comparison 1537 1433	prior
T94	Procedure 1547 1443	treatment
T95	Procedure 1556 1452	SCT
T96	And 1571 1467	but
T97	Negation 1575 1471	not
T98	Condition 1595 1491	GVHD
T99	Or 1598 1494	or
T100	Eq-Comparison 1617 1513	receiving
T101	Procedure 1635 1531	immunosuppression
T102	Or 1637 1532	/
T103	Procedure 1650 1544	GVHD therapy
T104	Condition-Name 55 51	AML
T105	Condition-Name 108 100	Refractory disease
T106	Eq-Operator 136 128	at least
T107	Eq-Value 139 130	1
T108	Eq-Temporal-Period 145 136	prior
T109	Condition-Name 205 192	Relapsed disease
T110	Eq-Value 227 213	5
T111	Eq-Unit 229 214	%
T112	Eq-Operator 237 222	or more
T115	Condition-Name 313 294	AML
T116	Condition-Name 352 333	myelodysplastic syndromes
T117	Condition-Name 369 349	CMML
T118	Condition-Name 403 382	myeloproliferative neoplasms
T119	Condition-Name 419 397	AML
T120	Condition-Name 430 405	ts-AML
T121	Observation-Name 484 454	Circulating blast count
T122	Eq-Operator 486 456	≤
T123	Eq-Value 491 460	200
T124	Eq-Operator 503 470	within
T125	Eq-Value 507 473	10
T126	Eq-Temporal-Unit 512 478	days
T127	Eq-Temporal-Recency 527 493	first
T128	Drug-Name 561 525	Hydroxyurea
T129	Eq-Operator 613 577	≤
T130	Eq-Value 618 581	200
T131	Observation-Name 715 673	ECOG
T132	Observation-Name 759 713	Estimated creatinine clearance
T133	Eq-Operator 761 715	≥
T134	Eq-Value 765 718	50
T135	Eq-Unit 768 721	mL
T136	Eq-Temporal-Unit 774 725	min
T137	Observation-Name 785 734	AST
T138	Observation-Name 793 742	ALT
T139	Eq-Operator 795 744	≤
T140	Eq-Value 800 748	3.0
T141	Observation-Name 823 769	Bilirubin
T142	Eq-Operator 825 771	≤
T143	Eq-Value 830 775	3.0
T144	Eq-Temporal-Period 872 813	Active
T145	Condition-Name 885 826	Leukemia
T146	Condition-Name 915 852	HIV infection
T148	Condition-Name 961 898	infection
T149	Observation-Name 992 928	viral load
T150	Eq-Temporal-Period 1030 960	received
T151	Polarity 1055 983	moderate
T152	Drug-Name 1071 998	CYP3A inducers
T153	Eq-Operator 1078 1005	within
T154	Eq-Value 1081 1007	7
T155	Eq-Temporal-Unit 1086 1012	days
T156	Eq-Temporal-Recency 1110 1036	initiation
T157	Eq-Temporal-Period 1159 1081	received prior
T158	Procedure-Name 1169 1091	radiation
T159	Severity 1215 1137	critical
T160	Polarity 1222 1144	normal
T161	Severity 1261 1179	significant
T162	Condition-Name 1277 1195	cardiac disease
T163	Eq-Temporal-Period 1294 1208	Active
T164	Severity 1317 1230	serious
T165	Condition-Name 1327 1240	infection
T166	Condition-Name 1373 1280	malignancy
T167	Eq-Operator 1380 1287	within
T168	Eq-Value 1383 1289	2
T169	Eq-Temporal-Unit 1389 1295	years
T170	Condition-Name 1450 1349	Psychiatric disorder
T171	Eq-Temporal-Period 1506 1403	Previous
T172	Procedure-Name 1529 1426	organ transplant
T173	Eq-Temporal-Period 1537 1433	prior
T174	Procedure-Name 1556 1452	SCT
T175	Condition-Name 1595 1491	GVHD
T176	Eq-Temporal-Period 1617 1513	receiving
T177	Procedure-Name 1635 1531	immunosuppression
T178	Procedure-Name 1650 1544	GVHD therapy
T6	Eq-Comparison 145 136	prior
T179	Condition-Name 173 164	remission
T180	And 160 151	with
T12	Observation 259 244	blasts in bone marrow
T14	Observation-Name 244 229	blasts
T113	Observation-Specimen 259 244	bone marrow
T15	Condition-Name 280 265	remission
T114	Eq-Unit 496 463	μL
T33	Observation-Name 611 575	peripheral blast count
T34	Eq-Unit 623 584	μL
T181	Eq-Temporal-Recency 643 604	first day
T40	Assertion 576 540	should be used
T182	Eq-Operator 717 675	≤
T183	Eq-Value 720 677	2
T44	Eq-Unit 806 754	ULN
T184	Eq-Unit 836 781	ULN
T57	Modifier 951 888	hepatitis C
T147	Polarity 981 917	detectable
T61	Polarity 1037 967	strong
T65	Modifier 1199 1121	maximally tolerated levels
T74	Negation 1352 1261	non
A4	Temporal-Connection-Type-Value E16 after
A5	Temporal-Connection-Type-Value E29 before
A8	Temporal-Connection-Type-Value E37 before
A10	Temporal-Connection-Type-Value E68 before
A11	Temporal-Connection-Type-Value E84 before
A12	Assertion-Type-Value E87 hypothetical
A13	Eq-Operator-Value T106 GTEQ
A14	Eq-Temporal-Period-Value T108 past
A15	Eq-Operator-Value T112 GTEQ
A17	Observation-Type-Value T121 lab
A18	Eq-Operator-Value T122 LTEQ
A19	Eq-Operator-Value T124 LTEQ
A20	Eq-Temporal-Unit-Value T126 day
A21	Eq-Temporal-Recency-Value T127 first-time
A22	Eq-Operator-Value T129 LTEQ
A23	Observation-Type-Value T132 lab
A24	Eq-Operator-Value T133 GTEQ
A25	Eq-Temporal-Unit-Value T136 minute
A26	Observation-Type-Value T137 lab
A27	Observation-Type-Value T138 lab
A28	Eq-Operator-Value T139 LTEQ
A29	Observation-Type-Value T141 lab
A30	Eq-Operator-Value T142 LTEQ
A31	Eq-Temporal-Period-Value T144 present
A32	Observation-Type-Value T149 lab
A33	Eq-Temporal-Period-Value T150 past
A35	Eq-Operator-Value T153 LTEQ
A36	Eq-Temporal-Unit-Value T155 day
A37	Eq-Temporal-Recency-Value T156 first-time
A38	Eq-Temporal-Period-Value T157 past
A39	Severity-Value T159 severe
A40	Polarity-Value T160 normal
A41	Severity-Value T161 severe
A42	Eq-Temporal-Period-Value T163 present
A43	Severity-Value T164 severe
A44	Eq-Operator-Value T167 LTEQ
A45	Eq-Temporal-Unit-Value T169 year
A46	Eq-Temporal-Period-Value T171 past
A47	Eq-Temporal-Period-Value T173 past
A48	Eq-Temporal-Period-Value T176 present
A1	Observation-Type-Value T14 lab
A2	Observation-Type-Value T33 lab
A3	Eq-Temporal-Recency-Value T181 first-time
A6	Assertion-Type-Value E14 hypothetical
A7	Eq-Operator-Value T182 LTEQ
A9	Polarity-Value T147 positive
A49	Polarity-Value T151 medium
A16	Polarity-Value T61 high
R1	Equivalent-To Arg1:E8 Arg2:E5
R2	Equivalent-To Arg1:E12 Arg2:E11
R3	Caused-By Arg1:E18 Arg2:E19
R4	Abbrev-Of Arg1:E20 Arg2:E19
R5	Caused-By Arg1:E18 Arg2:E22
R6	Abbrev-Of Arg1:E24 Arg2:E22
R7	Abbrev-Of Arg1:E25 Arg2:E22
R8	Caused-By Arg1:E35 Arg2:E32
R9	Found-By Arg1:E60 Arg2:E62
R10	Found-By Arg1:E55 Arg2:E62
R11	Caused-By Arg1:E88 Arg2:E86
R12	Using Arg1:E94 Arg2:E95